EMA has issued final scientific advice clearing Clinuvel’s pivotal vitiligo trial to use a “totality of evidence” assessment anchored by centrally adjudicated photography. The Phase III CUV107 study will enroll 300 adults and adolescents with non-segmental vitiligo, comparing afamelanotide (SCENESSE) plus adjunct narrowband UVB to NB-UVB monotherapy. T‑VASI50 will serve as the primary endpoint, F‑VASI75 as a key secondary, with multiple patient-reported outcomes integrated. Central photographic review and validated disease assessment tools are built into the design. Study start is targeted for the second half of 2026.
The core development is regulatory: after a year of interactions, EMA’s CHMP/SAWP endorsed an approach that blends clinical endpoints, photographic evidence, and PROs, and will consider data from prior afamelanotide vitiligo studies in the final benefit–risk evaluation. EMA highlighted that patient perception of visible repigmentation will carry meaningful weight, and indicated patients with darker skin types (Fitzpatrick IV–VI), where contrast is highest, may be positioned to benefit first from a systemic option. The design choice to mandate a central photographic read for both primary and secondary measures signals a tight emphasis on objective, reproducible documentation of repigmentation alongside functional and patient-reported change.
Strategically, Clinuvel is pursuing the systemic space in a field where approved therapies to date largely address limited body surface area and rely on topical mechanisms. Pairing afamelanotide with NB-UVB grounds the program in an accepted standard, but also raises the bar to show additive benefit over an active comparator. The “totality of evidence” stance gives Clinuvel latitude to leverage earlier trials and PRO signals rather than hinge approval on a single numeric threshold, potentially de-risking the dossier if the Phase III delivers consistent, multi-source efficacy. It also reflects a broader regulatory trend in dermatology toward multimodal efficacy demonstrations that capture both visible and patient-valued outcomes.
Operationally, the guidance has immediate implications for sites and vendors. Centralized photographic adjudication will require rigorous imaging SOPs, calibrated lighting, and training to minimize variability across geographies and skin tones. NB-UVB capacity and scheduling must support frequent visits, and sites will need implant administration capability for afamelanotide, adding procedure logistics to phototherapy workflows. ePRO implementation and multiple survey instruments will increase data-capture complexity and monitoring needs. For CROs and imaging providers, the study favors partners with dermatology imaging experience, robust QC pipelines, and the ability to harmonize NB-UVB regimens and metadata across a multinational footprint. Recruitment plans will have to over-index on skin-of-color representation, historically a bottleneck in dermatology trials, with site selection and community engagement aligned accordingly.
What to watch next is whether Clinuvel harmonizes its endpoint and evidence strategy with FDA, where VASI-based measures are established but the regulatory weight of photographic reads and aggregated prior-study data may differ from EMA’s stance. Protocol details will be telling: stratification by Fitzpatrick type and baseline body surface area, durability and maintenance assessments, standardization of NB-UVB devices and dosing schedules, and the handling of adolescent subpopulations. Key risks center on imaging variability, adherence to NB-UVB visit cadence, and signal detectability against an active comparator. With first patient in not expected until 2H 2026, the near-term milestones will be vendor selection, site readiness for imaging and implants, and clarity on geographic site mix to meet enrollment and diversity targets. If the trial can deliver a coherent efficacy narrative across central reads and PROs, the EMA’s framework could shorten the path to a European filing—and set a template for systemic vitiligo trials that lean on integrated evidence rather than single-point endpoints.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
